Explore the words cloud of the EARLYDETECT project. It provides you a very rough idea of what is the project "EARLYDETECT" about.
The following table provides information about the project.
Coordinator |
THE UNIVERSITY OF BIRMINGHAM
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Total cost | 0 € |
EC max contribution | 150˙000 € (0%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2019-PoC |
Funding Scheme | ERC-POC-LS |
Starting year | 2020 |
Duration (year-month-day) | from 2020-06-01 to 2021-11-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | THE UNIVERSITY OF BIRMINGHAM | UK (BIRMINGHAM) | coordinator | 150˙000.00 |
Every year, ovarian cancer (OC) kills more than 40 000 women in Europe and 150 000 worldwide. In large part this is due to the fact that most women are not diagnosed until advanced stages. There is an urgent unmet clinical need for screening tools for the early, accurate identification of OC. OC is associated with alterations in glycosylation of secreted glycoproteins, and as such, they can serve as early OC biomarkers. However, this knowledge has still not been translated into clinic due to the lack of assays that can differentiate subtle differences between glycan chains. For the first time, under the ERC consolidator grant-GLYCOSURF, we developed a synthetic glycan recognition platform that can sharply discriminate between different overall glycan structures (Patent No: WO2015/118294). Capitalizing on the knowledge of glycosylation variations in OC and our unique glycan recognition technology, we will be developing and clinically validating a new glycan-based test for detecting OC earlier and more effectively through a simple serum test. OC-associated glycans will be molecularly casted on fluorescent nanoparticles to create surface nanopockets with glycan receptors in a specific spatial arrangement to fit only OC-associated glycans. A microplate immunoassay with high sensitivity, selectivity and reproducibility will be developed, wherein the glycan-casted nanoparticles will provide a means for selectivity, signal amplification and fluorescent readout. Serum samples from OC patients and controls from women with benign tumours will be tested. The assay will be minimally-invasive, cost-effective and will be suitable for rapid, easily automatable, high-throughput screening, promoting swift translation into the clinical setting. This project offers therefore the potential to radically change the diagnostic standard of care for OC, ultimately saving lives and reducing the health, social and economic burden imposed by OC.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EARLYDETECT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EARLYDETECT" are provided by the European Opendata Portal: CORDIS opendata.